ICON PLC
| Company type | Public |
|---|---|
| Industry | Healthcare intelligence, Clinical research |
| Founded | 1 January 1990 in Dublin, Ireland |
| Founder | John Climax, Ronan Lambe |
| Headquarters | Dublin , Ireland |
Area served | Worldwide |
Key people | Steve Cutler (CEO until Oct 2025), Barry Balfe (CEO from Oct 2025) |
Number of employees | 41,900 (2025) |
| Website | www |
ICON plc is a global healthcare intelligence and clinical research organization headquartered in Ireland. By February 2025, the company employed around 41,900 individuals across 55 different countries.
History
Established in Dublin in 1990 by John Climax and Ronan Lambe, ICON expanded its international presence between 1991 and 1996, opening offices in the United Kingdom, United States, Germany, and Japan. The company went public on Nasdaq in 2008. John Climax remained a board member until at least 2010, while Ronan Lambe retired in 2018.
In March 2017, Steve Cutler was named CEO, bringing prior experience from IQVIA, Sandoz AG, and Kendle Intl Inc. Having joined ICON in 2011 as COO, he transitioned to CEO thereafter. During his tenure, ICON earned multiple accolades including PharmaTimes Clinical Researcher of the Year (2018), Clinical Research Company of the Year (2021), and Best Contract Research Organisation (FSP) at the 2022 Scrip Awards.
On September 4, 2025, ICON announced that Cutler would step down on October 1, 2025, with COO Barry Balfe appointed as his successor.
Acquisitions
- 2000: Acquired UK regulatory consultancy YRCR Ltd., a Central Laboratory based in New York, and bioanalytical consultancy Pacific Research.
- 2002: Purchased clinical research provider BPA.
- 2003: Added UK Phase I facility Medeval and US consulting firm Globomax to its portfolio.
- 2004: Acquired Beacon Bioscience Inc., specializing in medical imaging.
- 2006: Integrated Ovation Research Group, experts in outcomes research and health economics.
- 2007: Acquired European staffing company DOCS International.
- 2008: Added US phase I provider Healthcare Discoveries and bioanalytical laboratory Prevalere Life Sciences.
- 2009: Purchased UK biomarker laboratory Veeda Laboratories.
- 2010: Acquired Timaq Medical Imaging Inc.
- 2011: Integrated Oxford Outcomes, an international health outcomes consultancy, along with technology provider Firecrest Clinical.
- 2012: Acquired PriceSpective, a global value strategy consultancy, and Chinese CRO BeijingWits.
- 2013: Added ClinForce and Assent (staffing and FSP providers), plus EU pharmacovigilance specialist Akos.
- 2014: Purchased Aptiv Solutions, recognized for adaptive trial design and implementation.
- 2015: Acquired MediMedia Pharma Solutions to strengthen market access and scientific communications capabilities and PMG Research Inc., a US-based clinical research site network.
- 2016: Integrated Clinical Research Management Inc. to enhance presence in government-funded research.
- 2017: Acquired MAPI Group, elevating ICON to the position of the world’s second-largest late-phase service provider.
- 2019: Added Symphony Clinical Research (home-based patient services), MediNova (EMEA clinical research sites), and MolecularMD (molecular diagnostic testing).
- 2020: Purchased MedPass International, a leading European medical device CRO and regulatory consulting firm.
- 2021: Completed a $12 billion acquisition of PRA Health Sciences, a competitor in clinical research services; post-merger ownership was approximately split with ICON shareholders holding about 66% and PRA shareholders around 34%.
Finances
| Year | Revenue (thousands USD) |
Net Profit (thousands USD) |
Total Assets (thousands USD) |
Workforce (thousands) |
|---|---|---|---|---|
| 2020 | 2,797,288 | 332,964 | 3,435,606 | 15,730 |
| 2021 | 5,480,826 | 153,185 | 17,387,090 | 38,330 |
| 2022 | 7,741,386 | 505,304 | 17,185,278 | 41,100 |
| 2023 | 8,120,176 | 612,335 | 16,989,863 | 41,100 |
| 2024 | 8,281,676 | 705,051 | 16,877,678 | 41,900 |